Tropical Medicine and Infectious Disease
·
2023
·Vol. 8
·期 2
·105
·
IF 2.9
Fengyu Tian,Cong Jin,Shangzhi Ji,Yanqing Tie,Guohao Fan,Ruiqing Zhang,Yehuan Zheng,Xinxin Shen,Xuejun Ma,Zhishan Feng
Human immunodeficiency virus 1 (HIV-1) attacks the immune system, making people susceptible to various diseases, thus increasing their risk of death. Comprehensive detection of major HIV-1 strains circulating in China is vital for effective HIV-1 infection prevention and treatment. HIV-1 nucleic acid detection is considered effective for HIV-1 diagnosis since traditional immunological testing may fail to detect HIV-1 infection during the window period. This work demonstrates a one-pot two-stage amplification assay (RT-RAP), a combination of reverse transcription recombinase (RT- RAA), and quantitative real-time polymerase chain reaction (qRT-PCR). The turn-around time of the assay is only 50 min and can be performed with commonly available laboratory equipment, the qPCR devices. The RT-RAP assay could detect approximately 5 and 14 copies/reaction of HIV-1 DNA and RNA using recombinant plasmids and standard reference strains, respectively. Additionally, we found that the clinical performance of RT-RAP (detected 169 samples out of 170 specimens) was consistent with that of qRT-PCR. The sensitivity and specificity of RT-RAP were 100.00% (99/99) and 98.59% (70/71), respectively, while its positive and negative predictive values were 99.00% (99/100) and 100.00% (70/70), respectively. The total coincidence rate of the RT-RAP was 99.41% (169/170), with a kappa value of 0.988 (p< 0.05). We demonstrated that RT-RAP could rapidly detect the common HIV-1 subtypes commonly circulating in China with comparable sensitivity and specificity to qRT-PCR.Keywords:HIV-1;RT-RAA;qRT-PCR;clinical detection
研究领域:
病毒学
·
分子生物学
·
临床诊断
✓ 已验证
产品关联
DOI
PubMed
高影响因子
Virology Journal
·
2025
·
IF 3.8
Jinlei Guo,Yunfeng Shan,Ge Hu,Xiaojuan Zhu,Kangchen Zhao,Tao Wu,Qiao Qiao,Ying Chi,Lunbiao Cui,Yiyue Ge
Background Monkeypox virus (MPXV) infection has garnered significant global attention due to its rising incidence and substantial public health implications. A rapid, sensitive, and accurate diagnostic method is urgently required to enable early intervention and effective management of MPXV outbreaks. Results In this study, we developed a novel one-step assay that integrates loop-mediated isothermal amplification (LAMP) with CRISPR/Cas12b in one-pot for the detection of MPXV. The entire detection process did not require opening the lid of the reaction tube and could be completed within 40 min using extracted viral nucleic acids, which is faster than real-time quantitative PCR (qPCR). And the results could be interpreted through either real-time fluorescence or naked-eye visualization. The limit of detection (LOD) of the assay was demonstrated to be 6.5 copies per reaction and no cross-reactivity with other pathogens such as HSV, EBV, CVA16, EV-A71, and MV was found. Furthermore, when evaluated using 113 clinical samples, the assay achieved 100% sensitivity (71/71) and 100% specificity (42/42) compared to the qPCR. Conclusions In resource-limited settings, our method requires only a portable heat block or water bath and a blue light or ultraviolet flashlight for visual detection of MPXV, making it highly accessible. The integration of LAMP and CRISPR/Cas12b provides a robust, user-friendly platform for point-of-care testing, with promising potential for the rapid molecular diagnosis of infectious diseases. Supplementary Information The online version contains supplementary material available at 10.1186/s12985-025-02780-0.
研究领域:
医学
·
分子生物学
·
传染病学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
BIOSENSORS & BIOELECTRONICS
·
2023
·
IF 12.6
Yiqun Liu,Yaping Dong,Miao Hui,Lingyi Xu,Le Ye,Jicheng Lv,Li Yang,Yue Cui
The multiplex and simultaneous determination of blood glucose, creatinine and uric acid is essential for the early screening of chronic diseases or regular disease monitoring. Here, we report for the first time a biosensing array for the multiplex and simultaneous determination of plasma glucose, creatinine and uric acid. The sensing electrodes are fabricated on a PET surface, including three working electrodes, one reference electrode, and one counter electrode. Each specific enzyme is immobilized on its corresponding working electrode. The biosensing array can exhibit high sensitivity and selectivity for the simultaneous determination of blood glucose, creatinine and uric acid in real blood samples, and the measurement results are accurate and consistent with those from the clinical biochemistry analyzer in the hospital. It is expected that this work could provide new avenues for the fundamental study of biosensing device construction, as well as practical applications of the detection of biomarkers in chronic diseases.
研究领域:
生物传感器
·
临床化学
·
医疗器械
✓ 已验证
产品关联
DOI
PubMed
高影响因子
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
·
2019
·
IF 2.983
Fábio de Souza Barbosa,Leonardo Capra Pezzi,Marisa Tsao,Sandra Manoela Dias Macedo,Tiago Franco de Oliveira,Elfrides E.S. Schapoval,Andreas S.L. Mendez
An ESI-MS/MS method through direct infusion was validated for quantitative analysis of meropenem powder for injection. The validation parameters were established in a rapid analysis of 30 s. Drug stability was studied through the submission to stress testing, resulting on four degradation products. Under hydrolytic conditions, in acid, neutral and alkaline media, the major degradation product was formed through the cleavage of the β-lactam ring. Oxidation of the drug using H 2 O 2 (3%) showed the formation of two degradation products from a decarboxylation reaction and N-oxide formation. Under high humidity conditions, there was detected a dimer product. The stability of meropenem after reconstitution was studied in conditions that simulate its clinical use. In samples reconstituted and diluted in infusion fluids, an extensive degradation was observed. At room temperature meropenem maintained its content > 90% for up to 4 h when prepared in 5% glucose and for up to 12 h when prepared in 0.9% NaCl. Through ESI-MS/MS analyzes it was observed a degradation product formed by β-lactam ring cleavage, detected in all conditions studied. It was also identified a degradation product formed only in 5% glucose, generated by the hydrolysis of β-lactam followed by the attachment of a glucose molecule to the nitrogen of the pyrrolidine ring. In general, all the results obtained in the stability studies contribute to the knowledge about this antibiotic and future candidates of this class.
研究领域:
药学
·
分析化学
·
药物代谢
✓ 已验证
DOI
PubMed
高影响因子
TALANTA
·
2025
·
IF 6.1
Zihan Wang,Yihong Chen,Zexian Chen,Jiarong Duan,Huiping Wang,Erhua Guo,Jianhui Zhi,Shaomin Shuang,Chuan Dong,Jun Li,Xiaojuan Gong
Designing and developing a simple and reliable method for detecting disease biomarkers is crucial for early disease prevention and diagnosis. Fe-functionalized carbon quantum dot (Fe-CQD), synthesized from natural dandelion biomass through a controlled process, were developed as nanozymes with outstanding peroxidase-like activity. Uricase decomposes uric acid to release hydrogen peroxide (H 2 O 2 ), which the Fe-CQD nanozymes catalyze to produce reactive oxygen species (ROS) such as singlet oxygen ( 1 O 2 ) and hydroxyl radicals (•OH). These ROS then oxidize the colorless substrate o -phenylenediamine (OPD) into yellow 2,3-diaminophenazine (DAP), enabling visual detection of uric acid. Building on this principle, we have developed, for the first time, a visual sensing platform using Fe-CQD nanozymes. This platform integrates absorption spectra, a microplate reader, and smartphone-assisted visible-light imaging to detect uric acid, achieving detection limits as low as 0.31, 0.36, and 0.83 μM, respectively. The platform demonstrated excellent accuracy in clinical blood sample analysis, yielding results highly consistent with standard hospital methods and the UA Assay Kit-based colorimetric method. It also exhibited robust anti-interference capabilities and practicality, making it a reliable tool for UA detection in real-world clinical settings. This innovative platform highlights the potential of nanozymes in biomarker detection and lays a theoretical foundation for integrating intelligent, portable sensing technologies into clinical diagnostics.
研究领域:
生物化学
·
医学诊断
·
纳米技术
✓ 已验证
产品关联
DOI
PubMed
高影响因子
Nanoscale
·
2018
·Vol. 10
·期 14
·6467-6473
·
IF 7.233
Hao-Hua Deng,Ke-Lin Li,Quan-Quan Zhuang,Hua-Ping Peng,Qiong-Qiong Zhuang,Ai-Lin Liu,Xing-Hua Xia,Wei Chen
Luminescent copper nanoclusters (CuNCs) constitute a very active research topic due to their unique properties and lower cost than gold and silver NCs. In this study, we report a new, facile, and rapid top-down etching method for synthesizing luminescent CuNCs, using Cu nanoparticles (CuNPs) as the precursor and ammonia (NH3) as the etchant. The etching mechanism is systematically investigated and the optical and structural properties of the obtained CuNCs are carefully studied. The NH3-triggered etching process is very fast and the newly generated CuNCs can emit strong green fluorescence with a high quantum yield. Moreover, by coupling the urease-catalyzed hydrolysis of urea with the NH3-induced etching of CuNPs, we developed a novel fluorescence turn-on assay for urea. The linear range for urea detection is from 0.25 to 5 mM, and the limit of detection is 0.01 mM. This novel sensing approach, with good sensitivity and excellent selectivity, is then successfully utilized to detect urea in human serum samples, demonstrating its great potential in clinical diagnosis. In addition, the proposed coupling method can be extended to monitor other analytes that influence the size-focusing etching process, allowing metal NCs to be used to construct diverse chemosensors and biosensors.
研究领域:
材料科学
·
分析化学
·
生物医学
✓ 已验证
DOI
PubMed
高影响因子
SEMINARS IN NEUROLOGY
·
2017
·Vol. 37
·期 05
·481-482
·
IF 1.891
David M. Greer
The Guest Editor of this issue of Seminars in Neurology is Dr Joshua P. Klein. Dr Klein is the Associate Professor of Neurology and Radiology at the Harvard Medical School (HMS) and the founding Chief of the Division of Hospital Neurology in the Department of Neurology at the Brigham and Women's Hospital (BWH). Dr Klein is from New York and graduated with honors from the University of Pennsylvania in 1997 and then from the Medical Scientist Training Program at the Yale University School of Medicine in 2005. He is a 2009 graduate of the Harvard (BWH/MGH) Neurology Residency Program where he served as the Chief Resident in his final year. He then completed a fellowship in Diagnostic Neuroimaging at the BWH and is board certified in both Neurology and Neuroimaging. He serves as the Chair of the Membership Committee, member of the Board of Directors, and Secretary of the Executive Committee of the American Society of Neuroimaging . He served as the Chair of the Neurohospitalist Section of the American Academy of Neurology from 2015 to 2017 and is the Section Leader of the RITE Advisory Panel for Neuroimaging. He is a member of the Board of Directors of the Neurohospitalist Society . In addition, he is a member of the Editorial Board of Access Medicine Neurology (McGraw Hill) and Scientific Chair of the Audio Digest Foundation Neurology Board Review Course. At the BWH, he serves as the Clinical Service Director for Inpatient Neurology and Chair of the Neurology Finance Committee. Here, he also served for several years as the Director of Performance Improvement for Neurology. He previously served as the Associate Director of the Neurology Medical Student Clerkship and is the Society Head of the HMS Neuroanatomy Laboratory, where he taught for 10 years. He additionally serves as an Advisor for Best Doctors Inc., Advance Medical Inc., and DocFlight Inc., and is on the Scientific Advisory Board for Aladdin Inc. Dr Klein has participated in neuroimaging research across many areas of clinical neurology, including neuroinflammatory diseases, traumatic brain injury, and neurotoxicity related to cancer therapy. He has published over 70 journal articles, as well as chapters in major textbooks of neurology, hospital medicine, neurosurgery, and psychiatry. He is a frequent lecturer at national and international conferences and has directed or participated in medical education courses in Havana, Pune, Paris, Dubai, and Manila. With Drs Allan H. Ropper and Martin A. Samuels, he coauthored the 10th edition of the textbook “Adams and Victor's Principles of Neurology,” and is also coauthoring the upcoming 11th edition of the same title. Among many clinical and teaching awards, Dr Klein received the HMS Miyawaki Faculty Teaching Award in 2009, the BWH/MGH Neurology Faculty Teacher of the Year Award in 2012, and was selected as a Distinguished Clinician at the BWH in 2017. He is a Fellow of the American Neurological Association , the American Society of Neuroimaging , and the American Academy of Neurology . I greatly appreciate the efforts of Dr Klein, as well as of all the contributing authors, for their superb and insightful work in this issue of Seminars in Neurology , which provides a stellar update of the ever-changing field of neuroimaging. The issue provides not only practical advice to the practicing clinicians, but also deep insights into the cutting-edge research that is taking place rapidly in this field. On a personal note, I express warm thanks to my friend and colleague, Josh, who has been a leader in the field and a mentor to many. We hope you enjoy this marvelous issue!
研究领域:
神经科学
·
医学
✓ 已验证
DOI
PubMed
高影响因子
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
·
2022
·Vol. 130
·期 5
·592-605
·
IF 3.688
Zhiping Jin,Qingfeng He,Xiao Zhu,Mingshe Zhu,Yike Wang,Xin-an Wu,Qianzhou Lv,Xiaoqiang Xiang
Anlotinib is a small molecule of novel tyrosine kinase inhibitor initially approved to treat non-small cell lung cancer in China. Drug–drug interaction (DDI) is an extrinsic factor important for the appropriate use of anlotinib in clinical practice. In vitro experiments demonstrated that anlotinib is a substrate of cytochrome P450 (CYP) enzymes and moderate inhibitor of several common ones; however, no clinical DDI studies have been performed to investigate inhibitory effects of anlotinib on these CYP enzymes. Thus, its drug label recommends avoiding co-administration with substrates of these enzymes, which have narrow therapeutic windows. In this study, we performed a CYP450 inhibition study, followed by gathering in vitro and clinical pharmacokinetic data to build the first physiologically based pharmacokinetic (PBPK) model of anlotinib. The verified model was subsequently used to predict the DDI mediated by anlotinib. As a result, the marginal plasma exposure changes of typical CYP3A and CYP2C9 substrates were less than the bioequivalence threshold, indicating that anlotinib has a very low potential of causing clinically meaningful DDI through the inhibition of several major CYP enzymes. According to the FDA's latest guideline on DDI, the established model with the simulation results may support the revision of anlotinib labelling without further clinical studies, lifting unnecessary restrictions on anlotinib regimens.
研究领域:
药理学
·
临床药学
✓ 已验证
DOI
高影响因子
SEPARATION AND PURIFICATION TECHNOLOGY
·
2025
·
IF 9
Qi Zheng,Fan Wang,Jiayu Sun,Mohammed F. Hamza,Qiang Wu,Yehuizi Wu,Ningchao Zheng,Shunyan Ning,Tianjiao Jiang,Deqian Zeng,Hiroshi Watabe,Hao Wu,Yan Wu,Yuezhou Wei,Xiangbiao Yin
As the primary fission product in spent nuclear fuel being generally filed into the high-level liquid waste, the 90 Sr recovered from the reprocessed nuclear fuel could be a significant source for producing 90 Y nuclide (the decay daughter). It presents as one favorable therapeutic radionuclide candidate for radiolabeling of pharmaceuticals in widespread clinical application. Under this situation, a novel silica-based adsorbent (HDEHP/SiO 2 -P) was developed for selective separation of Y 3+ from concentrated Sr 2+ in aqueous solution. Batch adsorption process was investigated under different parameters of acid type and strength, contact time, temperature, ionic concentration and molar ratio etc. It was confirmed that, the HDEHP/SiO 2 -P had highly selective properties toward Y 3+ over Sr 2+ in different acidic medium (i.e., hydrochloric, nitric and acetic acid), with maximum adsorption capacity 34.05 mg Y 3+ /g. Sorption isotherms and uptake kinetics, were better fitting for Langmuir monomolecular layer adsorption mode and the pseudo-second order (PSORE) kinetic model respectively. The sorbent shows high SF Y/Sr of 1.93 × 10 3 even at a Sr-Y molar ratio of 2 × 10 3 . Moreover, dynamic separation of trace amount of Y 3+ from the concentrated Sr 2+ aqueous solution was successfully validated by the column test, in which 100 % Y 3+ was recovered. The produced eluate is characterized by a sharp elution curve without Sr trailing under high acidic conditions of 6 M HCl. All these results would promisingly promote the application of the developed material and chromatographic approach to facilely obtain the adequate quantities of 90 Y with required radiochemical purity for its widespread clinical use.
研究领域:
核化学与放射化学
·
材料科学
·
医学
✓ 已验证
产品关联
DOI
高影响因子
MOLECULES
·
2023
·Vol. 28
·期 2
·656
·
IF 4.6
Chanyi Li,Jiaying Qin,Wuping Liu,Bo Lv,Ning Yi,Jinfeng Xue,Zhigang Xue
Background: Homocysteine (Hcy) has been found to be closely related to the occurrence of diabetes mellitus (DM) and is considered as one of the risk factors of DM. However, Hcy alone is not enough as a factor to predict DM, and our study analyzed and determined the relationship between the main metabolites involved in the Hcy metabolic pathway and DM. Methods: A total of 48 clinical samples were collected, including 18 health control samples and 30 DM samples. All standards and samples were detected by LC-QTOF-MS. Multivariate statistical analysis and k-means cluster analysis were performed to screen and confirm the metabolites significantly correlated with DM. Results: A total of 13 metabolites of the Hcy metabolic pathway were detected in the samples. The content of Hcy, cysteine, taurine, pyridoxamine, methionine, and choline were significantly increased in the DM group (p< 0.05). Hcy, choline, cystathionine, methionine, and taurine contributed significantly to the probabilistic principal component analysis (PPCA) model. The odds ratios (OR) of Hcy, cysteine, taurine, methionine, and choline were all greater than one. K-means cluster analysis showed that the Hcy, taurine, methionine, and choline were significantly correlated with the distribution of glucose values (divided into four levels: 10.5–11.7 mmol/L, 7.7–9.7 mmol/L, 6.0–6.9 mmol/L, and 5.0–5.9 mmol/L, respectively). Conclusion: Hcy, taurine, methionine, and choline can be used as risk factors for diabetes diagnosis and are expected to be used for the assessment of diabetes severity.Keywords:homocysteine metabolism;diabetes;LC-MS;clinical diagnosis
研究领域:
代谢组学
·
糖尿病研究
·
临床化学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
Journal of Materials Chemistry B
·
2025
·
IF 5.7
Jingqi Dong,Jialin Hu,Liqiang Liu,Aihua Qu,Hua Kuang,Chuanlai Xu
Kynurenine (KYN), a metabolite of tryptophan, is currently receiving increasing attention as one of the biomarkers for clinical disease monitoring. To realize the determination of KYN in human plasma samples in the clinic, a specific monoclonal antibody (mAb) against KYN was prepared based on the structural characteristics of KYN. By optimizing the detection conditions, we obtained anti-KYN mAb 1G10 with a sensitivity of 143.66 ng/mL, and established a colloidal gold immunochromatographic assay (CGCA) platform for the qualitative and quantitative analysis of KYN in human plasma samples, using CGCA strips to meet the needs of clinical testing. The recoveries of the strips for the determination of KYN in plasma samples were in the range of 85.22%–99.72%, which were validated by liquid chromatography–tandem mass spectrometry (LC-MS/MS), and results were in good agreement with the LC-MS/MS method, indicating that the accuracy of the prepared CGCA strips was high. Based on the characteristics of low cost, high throughput and good specificity, the test strips will be widely applicable for clinical determination.
研究领域:
医学
·
免疫学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
Nature Protocols
·
2025
·
IF 16
Xu Ziye,Lyu Yuexiao,Chen Haide,Chen Yu,Wang Yongcheng
Formalin-fixed paraffin-embedded (FFPE) samples represent a vast and valuable resource of patient material, often linked to extensive clinical history and follow-up data. However, achieving single-cell or single-nucleus RNA (sc/snRNA) profiling in these archived tissues remains challenging. To address this, we have developed snRandom-seq, a droplet- and random primer–based single-nucleus total RNA sequencing technology specifically designed for FFPE tissues. This method captures total RNAs by using random primers and demonstrates a low doublet rate (0.3%), increased RNA coverage and enhanced detection of non-coding and nascent RNAs compared to state-of-the-art high-throughput sc/snRNA-seq technologies. This protocol provides a comprehensive guide to isolating single nuclei from FFPE samples; performing in situ DNA blocking, reverse transcription and dA tailing reactions; barcoding single-nucleus droplets; and preparing sequencing libraries. The entire snRandom-seq process can be completed in 4 d. This platform serves as a powerful tool for snRNA-seq of clinical specimens, with broad applications in studying complex biological systems.
研究领域:
分子生物学
·
医学
·
生物信息学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
危险品化学品经营许可证（带存储）